Folic Acid vs. Methylfolate: Your MTHFR Gene Determines Which Form Actually Works for You

A surprising number of people take folic acid and get little benefit. Your body must change folic acid into methylfolate. Many people do this slowly because of MTHFR gene variants.

This means you may look “fine” on simple tests, yet still run low in cells. If you have an MTHFR variant, folic acid can leave more unmetabolized folic acid in your blood. You can avoid this by using methylfolate instead.

Take 400–800 mcg of 5-MTHF daily for most goals. Recheck RBC folate in 12 weeks, not just serum folate. Also check homocysteine; aim for under 10 μmol/L. Confirm vitamin B12 is adequate before higher folate doses.

The methylenetetrahydrofolate reductase (MTHFR) gene produces the enzyme responsible for converting folic acid into methylfolate, the form your cells actually use [1]. Two common variants—C677T and A1298C—significantly reduce this enzyme's efficiency. The C677T variant alone affects 32-40% of the population, with those carrying two copies (homozygotes) showing 30-70% reduced enzyme activity [2].

This genetic bottleneck explains why folate research shows such inconsistent results. Studies conducted in populations with high MTHFR variant frequencies often show weaker responses to folic acid supplementation, while those in populations with fewer variants show stronger effects. The 'average' result masks enormous individual variation—some people convert folic acid efficiently, others barely convert it at all.

A landmark randomized controlled trial directly compared the two forms in 142 participants over 24 weeks. Those taking methylfolate achieved red blood cell folate levels 30% higher than those taking identical doses of folic acid [3]. This wasn't a small difference—it represented the gap between functional sufficiency and deficiency for many participants, despite both groups taking the same amount of 'folate' on paper.

If you take folic acid, your body must convert it into methylfolate (5-MTHF) before your cells can use it [1]. The MTHFR enzyme helps run that conversion. Two common gene variants—C677T and A1298C—can lower enzyme activity and slow the step that makes 5-MTHF [2].

This helps explain why folate studies can disagree. People with faster conversion often respond to folic acid. People with slower conversion may not, even at the same labeled dose.

What you should take from this is simple: “folate” is not one thing. The form matters. If conversion is slow, folic acid can leave you short on active folate inside cells, even when your supplement routine looks correct on paper.

When folic acid intake exceeds your ability to convert it, some of it can remain in circulation as unmetabolized folic acid (UMFA). UMFA has been measured in many adults in countries with folic-acid fortification [7]. Researchers are still working out what level matters and for whom.

One clear risk is clinical, not theoretical. High folate intake can mask vitamin B12 deficiency by improving the blood-count pattern of anemia while neurological injury from low B12 continues [7]. That is why folate and B12 should be assessed together.

Practical takeaway: do not use high-dose folic acid as a “just in case” strategy. If you supplement folate, confirm B12 status and consider using 5-MTHF, which avoids the folic-acid conversion bottleneck.

Folate can support cardiovascular markers, but average results hide big differences between people. In a meta-analysis of 21 randomized trials (2,025 participants), folic acid improved flow-mediated dilation by 2.59%, a marker of endothelial function [8]. In a separate meta-analysis of 34 trials (21,787 participants), folic acid lowered total cholesterol by 9.78 mg/dL on average [9].

These are group averages. Your result depends on baseline folate status, dose, study length, and whether you can generate enough active 5-MTHF. If conversion is slow, you may see smaller changes in homocysteine and vascular markers at the same folic-acid dose.

Mechanism matters here. Folate helps recycle homocysteine back into methionine, but that reaction uses methylfolate. If you do not make enough methylfolate, the downstream benefit can be limited even when folic acid intake is high [11].

Folate benefits are not just about “taking enough.” They depend on whether you can make the active form your cells use. If your MTHFR enzyme runs slower, standard folic acid may raise lab numbers without fully fixing cellular folate needs, and it can increase UMFA exposure. A simple, low-regret strategy is to use 5-MTHF, track RBC folate and homocysteine, and confirm adequate B12 before pushing doses higher.